TY - JOUR
T1 - Genotype-phenotype features of germline variants of the TMEM127 pheochromocytoma susceptibility gene
T2 - A 10-year update
AU - Armaiz-Pena, Gustavo
AU - Flores, Shahida K.
AU - Cheng, Zi Ming
AU - Zhang, Xhingyu
AU - Esquivel, Emmanuel
AU - Poullard, Natalie
AU - Vaidyanathan, Anusha
AU - Liu, Qianqian
AU - Michalek, Joel
AU - Santillan-Gomez, Alfredo A.
AU - Liss, Michael A
AU - Ahmadi, Sara
AU - Katselnik, Daniel
AU - Maldonado, Enrique
AU - Salgado, Sarimar Agosto
AU - Jimenez, Camilo
AU - Fishbein, Lauren
AU - Hamidi, Oksana
AU - Else, Tobias
AU - Lechan, Ron
AU - Tischler, Art S.
AU - Benn, Diana E.
AU - Dwight, Trisha
AU - Clifton-Bligh, Rory
AU - Sanso, Gabriela
AU - Barontini, Marta
AU - Vincent, Deepa
AU - Aronin, Neil
AU - Biondi, Bernadette
AU - Koops, Maureen
AU - Bowhay-Carnes, Elizabeth
AU - Gimenez-Roqueplo, Anne Paule
AU - Alvarez-Eslava, Andrea
AU - Bruder, Jan M.
AU - Kitano, Mio
AU - Burnichon, Nelly
AU - Ding, Yanli
AU - Dahia, Patricia L.M.
N1 - Publisher Copyright:
© 2020 The Author(s) 2020.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Purpose: This work aimed to evaluate genotype-phenotype associations in individuals carrying germline variants of transmembrane protein 127 gene (TMEM127), a poorly known gene that confers susceptibility to pheochromocytoma (PHEO) and paraganglioma (PGL). Design: Data were collected from a registry of probands with TMEM127 variants, published reports, and public databases. Main Outcome Analysis: Clinical, genetic, and functional associations were determined. Results: The cohort comprised 110 index patients (111 variants) with a mean age of 45 years (range, 21-84 years). Females were predominant (76 vs 34, P <. 001). Most patients had PHEO (n = 94; 85.5%), although PGL (n = 10; 9%) and renal cell carcinoma (RCC, n = 6; 5.4%) were also detected, either alone or in combination with PHEO. One-third of the cases had multiple tumors, and known family history was reported in 15.4%. Metastatic PHEO/PGL was rare (2.8%). Epinephrine alone, or combined with norepinephrine, accounted for 82% of the catecholamine profiles of PHEO/PGLs. Most variants (n = 63) occurred only once and 13 were recurrent (2-12 times). Although nontruncating variants were less frequent than truncating changes overall, they were predominant in non-PHEO clinical presentations (36% PHEO-only vs 69% other, P <. 001) and clustered disproportionately within transmembrane regions (P <. 01), underscoring the relevance of these domains for TMEM127 function. Integration of clinical and previous experimental data supported classification of variants into 4 groups based on mutation type, localization, and predicted disruption. Conclusions: Patients with TMEM127 variants often resemble sporadic nonmetastatic PHEOs. PGL and RCC may also co-occur, although their causal link requires further evaluation. We propose a new classification to predict variant pathogenicity and assist with carrier surveillance.
AB - Purpose: This work aimed to evaluate genotype-phenotype associations in individuals carrying germline variants of transmembrane protein 127 gene (TMEM127), a poorly known gene that confers susceptibility to pheochromocytoma (PHEO) and paraganglioma (PGL). Design: Data were collected from a registry of probands with TMEM127 variants, published reports, and public databases. Main Outcome Analysis: Clinical, genetic, and functional associations were determined. Results: The cohort comprised 110 index patients (111 variants) with a mean age of 45 years (range, 21-84 years). Females were predominant (76 vs 34, P <. 001). Most patients had PHEO (n = 94; 85.5%), although PGL (n = 10; 9%) and renal cell carcinoma (RCC, n = 6; 5.4%) were also detected, either alone or in combination with PHEO. One-third of the cases had multiple tumors, and known family history was reported in 15.4%. Metastatic PHEO/PGL was rare (2.8%). Epinephrine alone, or combined with norepinephrine, accounted for 82% of the catecholamine profiles of PHEO/PGLs. Most variants (n = 63) occurred only once and 13 were recurrent (2-12 times). Although nontruncating variants were less frequent than truncating changes overall, they were predominant in non-PHEO clinical presentations (36% PHEO-only vs 69% other, P <. 001) and clustered disproportionately within transmembrane regions (P <. 01), underscoring the relevance of these domains for TMEM127 function. Integration of clinical and previous experimental data supported classification of variants into 4 groups based on mutation type, localization, and predicted disruption. Conclusions: Patients with TMEM127 variants often resemble sporadic nonmetastatic PHEOs. PGL and RCC may also co-occur, although their causal link requires further evaluation. We propose a new classification to predict variant pathogenicity and assist with carrier surveillance.
KW - Genotype-phenotype association
KW - Paraganglioma
KW - Pheochromocytoma
KW - TMEM127
KW - Tumor suppressor gene
UR - http://www.scopus.com/inward/record.url?scp=85099072759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099072759&partnerID=8YFLogxK
U2 - 10.1210/clinem/dgaa741
DO - 10.1210/clinem/dgaa741
M3 - Article
C2 - 33051659
AN - SCOPUS:85099072759
SN - 0021-972X
VL - 106
SP - E350-E364
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 1
ER -